

GROUNDBREAKING TREND FOR PRESERVATIVE-FREE MULTIDOSE EYE DROPS IN THE US

In this article, Rouven Kraus, Head of Sales at Aero Pump, discusses the increasing trend towards preservative-free formulations in ophthalmic drug delivery and the challenges presented by regulatory demands on new drug products in the space.

INTRODUCTION

The ophthalmic drug market is expected to experience significant growth over the coming years due to the increasing prevalence of ophthalmic disorders. This is primarily attributable to factors such as increased life expectancy leading to ageing populations, increased air pollution and the rise in the number of patients diagnosed with diabetes. According to the WHO, approximately 2.2 billion people suffer from some form of visual impairment worldwide.1 Several market research reports predict a compound annual growth rate (CAGR) for the ophthalmic market of almost 8% from 2022 to 2030, which will reach around US\$68.9 billion (£57.3 billion) by 2030.2

Topically delivered eye drops are one of the most popular dosage forms for treating ophthalmic diseases. With a revenue share of around 40%, North America dominates the global market. According to available data, more than three million Americans are affected by glaucoma and only half of those are aware that they are affected. The National Eye Institute predicts that between 16 million and 49 million Americans suffer from dry eye symptoms, which accounts for 5%–15% of the population.³

There are several eye drop medications available to treat glaucoma, dry eye and other ocular diseases, with a multitude of different delivery technologies. Single-

dose vials are designed to dispense a single specified amount of medicine, and then be discarded. Of course, this leads to a lot of packaging waste. Furthermore, due to an unclean tear-off edge, there is a risk of injury to the eye during application.

Three-piece-droppers are conventional multidose bottles for preserved medications. Their squeeze mechanism can lead to an overdosing if the patient squeezes too hard and, towards the end, the force required to actuate them becomes higher and higher. Moreover, unlike single-dose vials, they are not suitable for use with preservativefree medications. Regulatory bodies recommend the use of preservative-free delivery technologies to protect the ocular surfaces from any side-effects that can be caused by common preservatives, such as benzalkonium chloride. Preservatives are known to be associated with toxic side effects, such as dry eye symptoms and trabecular meshwork degeneration.

THE SWITCH TO PRESERVATIVE-FREE

This recommendation by regulatory authorities has led ophthalmic manufacturers to a groundbreaking trend – switching their eye drops to use a preservative-free multidose (PFMD) delivery technology. One of the first PFMD ophthalmic drugs in the US has been Allergan's (Dublin, Ireland) blockbuster product Restasis® (cyclosporine) for the



Rouven Kraus Head of Sales T: +49 6146 6030 E: sales@aeropump.de

Aero Pump GmbHDr-Ruben-Rausing-Straße 5
65239 Hochheim
Germany

www.aeropump.de/en/

"This recommendation by regulatory authorities has led ophthalmic manufacturers to a groundbreaking trend – switching their eye drops to use a PFMD delivery technology."

treatment of chronic dry eye. While most eye drop-based medications are still offered in a preserved form, there is now a significant trend towards the use of preservative-free delivery platforms.

Industry and healthcare experts in the US are taking Europe as a pioneering example of this change. There, the switch to preservative-free medications took place more than two decades ago. Brands such as Ursapharm's (Saarbrücken, Germany) Hylo-COMOD® (sodium hyaluronate) eye drops for the treatment of dry eye or Bausch + Lomb's (Laval, Canada) Vizilatan (latanoprost) for glaucoma have been successfully launched on the market. Nowadays the majority of multidose eye drops in Europe come in preservative-free packaging. Looking at investigational new drug applications (INDs) registered at the US FDA, most new product developments in the US now also consider a preservative-free delivery technology for their ophthalmic drug product.



REGULATORY CHALLENGES OF COMBINATION PRODUCTS

The FDA has defined regulations for the development of drug-device combination products, which are applicable to most eye drop medications (Figure 1). A combination product is a product composed of any combination of a drug and another constituent part – the device – which can come prefilled by the manufacturer or simply co-packaged in the same box.⁴

Being classified as a combination product challenges device manufacturers to fulfil the requirements outlined in 21 CFR 820.30 for design controls. As such, manufacturers "Aero Pump offers device manufacturing services with a full regulatory understanding for its well-known 3K system."

of the device part of the combination product must record a device history file – a compilation of documentation providing evidence that the design was developed in accordance with the approved design plan and its requirements. Due to these new regulations, it is crucial for the applicant of the finished product to select a device manufacturer that can support them through the entire regulatory pathway.

Aero Pump offers device manufacturing services with a full regulatory understanding for its well-known $3K^{\oplus}$ system – a pump-driven delivery technology that applies a single metered drop per activation. Custom-fit regulatory packages support the application during the individual stages of the submission process.

AERO PUMP'S PRESERVATIVE-FREE OPHTHALMIC MULTIDOSE SYSTEM

Aero Pump's 3K pump eyedropper is well-established and has been on the market since its first product launch in 2006. It is the only eyedropper based on a purely mechanic pump technology that offers a metered dose. Special germ-reducing components inside the 3K system ensure



the microbiological safety of the device. The 3K pump is used in numerous approved over-the-counter and prescription drug products.

Various patient-friendly actuation aids enable the convenient application of a drop into the eye. Aero Pump's pharmaceutical customers can choose their preferred finger sleeve design, which can then be customised to meet the needs of the end user (Figure 2). Furthermore, the 3K system can be used with plastic or glass containers in various fill sizes, which is a particular advantage when attempting to reduce the interaction between the container and the product.

The 3K system delivers an accurate dose over the whole lifecycle of the product, with one metered drop per stroke. The actuation force of Aero Pump's ophthalmic multidose system is stable and independent of the residual liquid inside the container. The device will be CE-marked to accelerate the approval process of the drug product, and Aero Pump offers comprehensive support for a successful regulatory submission process.

ABOUT THE COMPANY

Aero Pump GmbH is a leading manufacturer of high-precision application systems for the pharmaceutical and healthcare industry, focused on innovation, multifunctionality and contemporary design. Its spray pumps and dropper systems are widely established in markets worldwide, primarily in the ophthalmic, respiratory and dermal fields, and are suitable for preserved and preservative-free overthe-counter and prescription drugs. The company has extensive knowledge in supporting pharmaceutical customers with custom-fit regulatory files for a successful submission.

REFERENCES

- 1. "Blindness and vision impairment". WHO. Oct 2022.
- "Ophthalmic Drugs Market Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2030". Precedence Research, Nov 2022.
- 3. "Eye-Drop And Lubricants Market By Product Type, By Application, By Geography - Global Opportunity Analysis & Industry Forecast, 2022-2027". Industry ARC, 2022.
- 4. "Regulation (EU) 2017/745 Article 117: Drug-device combination products application process". EMA, Apr 2017.

ABOUT THE AUTHOR

Rouven Kraus has more than 10 years of experience in the ophthalmic drug market. He started his career in sales for a domestic iron foundry in Mainz, Germany, and joined Aero Pump in 2012 to augment the sales of their drug delivery device portfolio. In his role he manages global sales and the company's strategic approach to new ophthalmic developments and delivery technologies.

Quote ONdrugDelivery and save \$100

PharmaED's

Extractables & Leachables Summit, 2023

Ensuring Quality, Safety, Suitability & Regulatory Compliance for Drugs, Biologics and Med Devices

Philadelphia, PA

17th-18th

April

2023



Conference Highlights Include:

- Designing and Improving Risk-Based Assessment of E&L Data for Drugs, Biologics, and Medical Devices
- Implementing ISO 10993-17 & ISO 10993-18 Standards
- AETs and Response Factor Variation for E/L Studies
- Uncertainty Factors Reconsidered: Toxicological & Chemistry Perspectives

Featured Speakers Include:

- David Saylor, FDA (on approval)
- Dennis Jenke, Triad Scientific
- Nicole Soucy, Boston Scientific
- Ping Wang, Janssen R&D
- Dujuan Lu, SGS

Register online at: www.pharmaedresources.com

For further info, contact Kim: (217) 721-5774, or email us: khubbard@pharmaedresources.com









Ophthalmic 3K® Multidose System

Metered Dose for Preservative-free Solutions

The only available metered dose PFMD technology for ophthalmics

The metered dose and exact reproducability of the drop size, based on the mechanical functionality of the pump, is unique amongst eye droppers.

Our prestigious 3K®-Pump delivers an accurate dose all over the lifecycle of the product. It is approved in various markets including Europe, USA, Far East and Latin America.

We are looking forward to your request!

www.aeropump.com sales@aeropump.de +49 6146 6030

Find the right product for your project!

Test the interactive Aero Pump Configurator now:



aeropump.com